{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:06:03Z","timestamp":1794618363673,"version":"4.9.1"},"reference-count":42,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>To determine whether a combination of baseline and change in spectral domain-optical coherence tomography (SD-OCT)-based biomarkers can predict visual outcomes in eyes with diabetic macular oedema (DMO) treated with antivascular endothelial growth factors (VEGF) injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective cohort study conducted in Hong Kong, China. 196 eyes with centre-involving DMO, who received anti-VEGF injections between 1 January 2011 and 30 June 2018 were recruited. Medical records of the participants were retrieved retrospectively, visual acuity (VA) at baseline, 6, 12 and 24 months and SD-OCT before initiation and after completion of anti-VEGF treatment were obtained. The SD-OCT images were evaluated for the morphology of DMO, vitreomacular status, presence of disorganisation of retinal inner layers (DRIL), sizes of intraretinal cysts, visibility of external limiting membrane (ELM), ellipsoid zone (EZ) and cone outer segment tip (COST) and the presence of hyper-reflective foci in retina or the choroid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The presence of baseline DRIL, hyper-reflective foci in retina and disruption of ELM\/EZ and COST were associated with worse baseline and subsequent VA up to 24 months after treatment. Improvement in DRIL (p=0.048), ELM\/EZ (p=0.001) and COST (p=0.002) disruption after treatment was associated with greater improvement in VA at 12 months. Eyes with cystoid macular oedema (p=0.003, OR=8.18) and serous retinal detachment (p=0.011, OR=4.84) morphology were more likely to achieve at least 20% reduction in central subfield thickness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and relevance<\/jats:title>\n                    <jats:p>Baseline SD-OCT biomarkers and their subsequent change predict VA and improvement in vision in eyes with DMO treated with anti-VEGF injections. We proposed an SD-OCT-based system that can be readily used in real-life eye clinics to improve decision making in the management of DMO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjophthalmol-2021-319587","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T13:30:12Z","timestamp":1636378212000},"page":"525-533","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study"],"prefix":"10.1136","volume":"107","author":[{"given":"Simon KH","family":"Szeto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian W. K.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang Yao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-7113","authenticated-orcid":false,"given":"Zi han","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheeda","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-3726","authenticated-orcid":false,"given":"Carmen K M","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y Y","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9672-1819","authenticated-orcid":false,"given":"Carol","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"2023032202150716000_107.4.525.1","article-title":"The prevalence of diabetic retinopathy among adults in the United States","volume":"122","author":"Kempen","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"2023032202150716000_107.4.525.2","doi-asserted-by":"crossref","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"2023032202150716000_107.4.525.3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30052-3"},{"key":"2023032202150716000_107.4.525.4","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2023032202150716000_107.4.525.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1111"},{"key":"2023032202150716000_107.4.525.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307382"},{"key":"2023032202150716000_107.4.525.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.10.006"},{"key":"2023032202150716000_107.4.525.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-Week results from the vista and vivid studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: rise and ride","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.10","doi-asserted-by":"crossref","first-page":"615-25","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The restore study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2016.09.012","article-title":"Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data","volume":"172","author":"Gonzalez","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2023032202150716000_107.4.525.12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/IAE.0b013e3181f04991","article-title":"Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema","volume":"31","author":"Shimura","year":"2011","journal-title":"Retina"},{"key":"2023032202150716000_107.4.525.13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/IAE.0b013e31826b6763","article-title":"Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema","volume":"33","author":"Shimura","year":"2013","journal-title":"Retina"},{"key":"2023032202150716000_107.4.525.14","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.152553"},{"key":"2023032202150716000_107.4.525.15","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2023032202150716000_107.4.525.16","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2015.0972","article-title":"Association of disorganization of retinal inner layers with vision after resolution of Center-Involved diabetic macular edema","volume":"133","author":"Radwan","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2023032202150716000_107.4.525.17","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-9231"},{"key":"2023032202150716000_107.4.525.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2010.01.039","article-title":"The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema","volume":"150","author":"Maheshwary","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"2023032202150716000_107.4.525.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2008.12.039","article-title":"Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema","volume":"116","author":"Bolz","year":"2009","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.20","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000001304","article-title":"Hyperreflective retinal spots in normal and diabetic eyes: B-scan and en face spectral domain optical coherence tomography evaluation","volume":"37","author":"Vujosevic","year":"2017","journal-title":"Retina"},{"key":"2023032202150716000_107.4.525.21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/APO.0000000000000249","article-title":"Choroidal hyperreflective foci: a novel spectral domain optical coherence tomography biomarker in eyes with diabetic macular edema","volume":"8","author":"Roy","year":"2019","journal-title":"Asia Pac J Ophthalmol"},{"key":"2023032202150716000_107.4.525.22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1120672119880394","article-title":"An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: the European school for advanced studies in ophthalmology classification","volume":"30","author":"Panozzo","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"2023032202150716000_107.4.525.23","article-title":"The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema","volume":"86","author":"Soliman","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"2023032202150716000_107.4.525.24","doi-asserted-by":"publisher","DOI":"10.1159\/000313820"},{"key":"2023032202150716000_107.4.525.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The reveal study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2009.03.006","article-title":"Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis)","volume":"148","author":"Grover","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"2023032202150716000_107.4.525.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2013.07.042","article-title":"The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole","volume":"120","author":"Duker","year":"2013","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.28","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/s41433-020-1100-0","article-title":"Sequential restoration of external limiting membrane and ellipsoid zone after intravitreal anti-VEGF therapy in diabetic macular oedema","volume":"35","author":"De","year":"2021","journal-title":"Eye"},{"key":"2023032202150716000_107.4.525.29","doi-asserted-by":"crossref","DOI":"10.1111\/aos.14230","article-title":"Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant","volume":"98","author":"Zur","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"2023032202150716000_107.4.525.30","doi-asserted-by":"crossref","DOI":"10.1007\/s00592-019-01424-4","article-title":"Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids","volume":"57","author":"Vujosevic","year":"2020","journal-title":"Acta Diabetol"},{"key":"2023032202150716000_107.4.525.31","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9950"},{"key":"2023032202150716000_107.4.525.32","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2023032202150716000_107.4.525.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.34","doi-asserted-by":"crossref","unstructured":"Bressler NM , Odia I , Maguire M , et al . Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab. JAMA Ophthalmol 2019;137:977.doi:10.1001\/jamaophthalmol.2019.1963","DOI":"10.1001\/jamaophthalmol.2019.1963"},{"key":"2023032202150716000_107.4.525.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2018.07.030","article-title":"Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T","volume":"195","author":"Bressler","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2023032202150716000_107.4.525.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2016.11.020","article-title":"Imaging of macrophage dynamics with optical coherence tomography in anterior ischemic optic neuropathy","volume":"154","author":"Kokona","year":"2017","journal-title":"Exp Eye Res"},{"key":"2023032202150716000_107.4.525.37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/ceo.12557","article-title":"Diagnostic accuracy of disorganization of the retinal inner layers in detecting macular capillary non-perfusion in diabetic retinopathy","volume":"43","author":"Nicholson","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"2023032202150716000_107.4.525.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.39","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-3064"},{"key":"2023032202150716000_107.4.525.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0107-6"},{"key":"2023032202150716000_107.4.525.41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2017.10.031","article-title":"Fully automated detection and quantification of macular fluid in OCT using deep learning","volume":"125","author":"Schlegl","year":"2018","journal-title":"Ophthalmology"},{"key":"2023032202150716000_107.4.525.42","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315933"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2021-319587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:17:55Z","timestamp":1679462275000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2021-319587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,3,22]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/bjophthalmol-2021-319587"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319587","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]}}}